Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression
Open Access
- 5 July 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 32 (3) , 487-497
Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by slowly progressive bilateral renal cyst growth ultimately resulting in loss of kidney function and end-stage renal disease (ESRD). Disease progression rate and age at ESRD are highly variable. Therapeutic interventions therefore require early risk stratification of patients and monitoring of disease progression in response to treatment. Methods: We used a urine peptidomic approach based on capillary electrophoresis–mass–spectrometry (CE-MS) to identify potential biomarkers reflecting the risk for early progression to ESRD in the Consortium of Radiologic Imaging in Polycystic Kidney Disease (CRISP) cohort. Results: A biomarker-based classifier consisting of 20 urinary peptides allowed the prediction of ESRD within 10–13 years of follow-up in patients 24–46 years of age at baseline. The performance of the biomarker score approached that of height-adjusted total kidney volume (htTKV) and the combination of the biomarker panel with htTKV improved prediction over either one alone. In young patients (2 glomerular filtration rate decline over 8 years. Sequence analysis of the altered urinary peptides and the prediction of the involved proteases by in silico analysis revealed alterations in distinct proteolytic pathways, in particular matrix metalloproteinases and cathepsins. Conclusion: We developed a urinary test that accurately predicts relevant clinical outcomes in ADPKD patients and suggests altered proteolytic pathways involved in disease progression.Keywords
This publication has 33 references indexed in Scilit:
- CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico dataBioinformatics, 2013
- Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric StudyPLOS ONE, 2013
- Urinary N-acetyl-β-D glucosaminidase as a surrogate marker for renal function in autosomal dominant polycystic kidney disease: 1 year prospective cohort studyBMC Nephrology, 2012
- Evaluation of urine biomarkers of kidney injury in polycystic kidney diseaseKidney International, 2012
- Reactome pathway analysis to enrich biological discovery in proteomics data setsProteomics, 2011
- Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney DiseaseMolecular & Cellular Proteomics, 2010
- The biomarker enriched proteome of autosomal dominant polycystic kidney disease cyst fluidProteomics – Clinical Applications, 2009
- ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networksBioinformatics, 2009
- Acceleration of polycystic kidney disease progression in cpk mice carrying a deletion in the homeodomain protein Cux1American Journal of Physiology-Renal Physiology, 2008
- Capillary electrophoresis–mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: An update of recent developmentsMass Spectrometry Reviews, 2008